Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sarah Wynn

Physician Assistant Marion, OH Physician Assistant

NPI 1669771192 CMS profile 11222877

1025 Harding Memorial Pkwy, Marion, OH 43302

Open in the dashboard

General payments

$9,871

661 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Wynn of Marion, OH is reported in the CMS Open Payments database as having received $9,871 across 661 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,483 86
2024 General $2,127 129
2023 General $1,970 135
2022 General $2,052 151
2021 General $2,239 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Wynn
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Sarah Wynn were reported at $1,483. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Sarah Wynn Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,239 $132 $37–$438 $132
2022 $2,052 $155 $48–$522 $149
2023 $1,970 $167 $52–$557 $160
2024 $2,127 $178 $55–$600 $164
2025 $1,483 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,461 102 payments
  2. AstraZeneca Pharmaceuticals LP $1,329 51 payments
  3. Novo Nordisk Inc $813 79 payments
  4. Pfizer Inc. $785 56 payments
  5. Lilly USA, LLC $697 48 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $619 51 payments
  7. GlaxoSmithKline, LLC. $525 44 payments
  8. Novartis Pharmaceuticals Corporation $331 18 payments
  9. Exact Sciences Corporation $328 17 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $260 17 payments
  11. Other $2,725 178 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,860 660 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. FARXIGA $941 27 payments
  2. BREZTRI $697 15 payments
  3. UBRELVY $670 45 payments
  4. Kerendia $619 51 payments
  5. Ozempic $484 54 payments
  6. RYBELSUS $470 53 payments
  7. TRELEGY ELLIPTA $454 38 payments
  8. NURTEC ODT Primary Care $428 33 payments
  9. AIRSUPRA $422 14 payments
  10. NURTEC ODT Pain $387 33 payments
  11. Other $7,246 481 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 107 drugs

Part D claims

4,163

Median for Physician Assistant: 241

Drug cost

$363,744

Median for Physician Assistant: $4,110

Branded share of claims

21.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 39 $47,300
Jardiance Empagliflozin Brand 29 $37,114
Trulicity Dulaglutide Brand 19 $31,731
Eliquis Apixaban Brand 28 $24,659
Farxiga Dapagliflozin Propanediol Brand 15 $22,250
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 26 $18,736
Xarelto Rivaroxaban Brand 14 $18,150
Myrbetriq Mirabegron Brand 22 $17,755
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 25 $16,366
Mounjaro Tirzepatide Brand 13 $14,604

The 10 drugs with the highest cost, of 107 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$31,665

Of which drugs: $3,292

Medicare patients

90

Average age 70

Services billed

842

47 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 36%
Diabetes 33%
Chronic kidney disease 24%
Depression 21%
COPD 20%
Atrial fibrillation 17%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 21 21 $1,718

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $154
$154 25 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $143
$143 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $105
$105 15 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $98
$98 — —
UBRELVY
  • AbbVie, Inc. $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

661 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record